Smartphone and tablet based point-of-care in vitro diagnostics and devices for mobile healthcare

2014 ◽  
Vol 20 (1) ◽  
pp. 25-26
Author(s):  
S.K. Vashist ◽  
Th. van Oordt ◽  
E.M. Schneider ◽  
F. von Stetten ◽  
R. Zengerle
Diagnostics ◽  
2016 ◽  
Vol 6 (3) ◽  
pp. 33 ◽  
Author(s):  
François Patou ◽  
Fatima AlZahra’a Alatraktchi ◽  
Claus Kjægaard ◽  
Maria Dimaki ◽  
Jan Madsen ◽  
...  

Author(s):  
Darwin R. Reyes ◽  
Henne van Heeren

In the last two decades, the microfluidics/lab-on-a-chip field has evolved from the concept of micro total analysis systems, where systems with integrated pretreatment and analysis of chemicals were envisioned, to what is known today as lab-on-a-chip, which is expected to be modular. This field has shown great potential for the development of technologies that can make, and to some extent are making, a big difference in areas such as in vitro diagnostics, point of care testing, organ on a chip, and many more. Microfluidics plays an essential role in these systems, and determining the standards needed in this area is critical for enabling new markets and products, and to advance research and development. Our goal was to bring together stakeholders from industry, academia, and government to discuss and define the needs within the field for the development of standards. This publication contains a summary of the workshop, abstracts from each presentation, and a summary of the breakout sessions from the National Institute of Standards and Technology Workshop on Standards for Microfluidics, held on June 1–2, 2017. The workshop was attended by 46 persons from 26 organizations and 11 countries. This was a unique and exciting opportunity for stakeholders from all over the world to join in the discussion of future developments towards standardization in the microfluidics arena.


BMJ Open ◽  
2015 ◽  
Vol 5 (7) ◽  
pp. e007840 ◽  
Author(s):  
Jeremy R Huddy ◽  
Melody Ni ◽  
Stella Mavroveli ◽  
James Barlow ◽  
Doris-Ann Williams ◽  
...  

2016 ◽  
Vol 34 (3) ◽  
pp. 137-138 ◽  
Author(s):  
Sandeep K. Vashist ◽  
John H.T. Luong

2018 ◽  
Vol 64 (10) ◽  
pp. 1439-1452 ◽  
Author(s):  
Ping Wang ◽  
Larry J Kricka

AbstractBACKGROUNDPoint-of-care technology (POCT) provides actionable information at the site of care to allow rapid clinical decision-making. With healthcare emphasis shifting toward precision medicine, population health, and chronic disease management, the potential impact of POCT continues to grow, and several prominent POCT trends have emerged or strengthened in the last decade.CONTENTThis review summarizes current and emerging trends in POCT, including technologies approved or cleared by the Food and Drug Administration or in development. Technologies included have either impacted existing clinical diagnostics applications (e.g., continuous monitoring and targeted nucleic acid testing) or are likely to impact diagnostics delivery in the near future. The focus is limited to in vitro diagnostics applications, although in some sections, technologies beyond in vitro diagnostics are also included given the commonalities (e.g., ultrasound plug-ins for smart phones). For technologies in development (e.g., wearables, noninvasive testing, mass spectrometry and nuclear magnetic resonance, paper-based diagnostics, nanopore-based devices, and digital microfluidics), we also discuss their potential clinical applications and provide perspectives on strategies beyond technological and analytical proof of concept, with the end goal of clinical implementation and impact.SUMMARYThe field of POCT has witnessed strong growth over the past decade, as evidenced by new clinical or consumer products or research and development directions. Combined with the appropriate strategies for clinical needs assessment, validation, and implementation, these and future POCTs may significantly impact care delivery and associated outcomes and costs.


Diagnostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1630
Author(s):  
Sandeep Kumar Vashist

The tremendous advances in multiplex immunoassays (MIAs) are leading to novel in vitro diagnostics (IVD) and point-of-care testing (POCT). MIAs can simultaneously detect numerous analytes in a single sample, which facilitates the diagnosis of many complex diseases. Various clinical score-based diagnostic algorithms have already been developed for several complex diseases, where the clinical score is determined by assigning appropriate weightage to various biomarkers based on their contribution to the disease. Despite a wide range of MIA formats being developed, only a few have been commercialized. There is a need for considerable improvements in MIAs so that they are analytically superior and can compete with the most extensively used automated IAs. The readout of most MIAs is still completed by bulky and expensive reader devices, which emphasizes the need for compact, handheld multiplex readers. Further, the clinical utility, reimbursement models, pathophysiological range of analytes, nature and dilution of samples, and the reagents used to develop an MIA need to be analyzed stringently. This manuscript provides guided insights into MIA formats and discusses the challenges and future directions.


Author(s):  
David P. Klemer

The array of tools available to the medical practitioner for diagnosis of disease has experienced extremely rapid expansion over the past decades. Traditional “blood chemistries” and hematological testing have been augmented with immunoassays for serological testing and PCR-based assays for genomic screening. Rapid, inexpensive point-of-care assays with enhanced sensitivity and specificity have the potential for altering the manner in which medicine is practiced; pharmacogenomics and the advent of “personalized medicine” permit the tailoring of therapeutic pharmacologic regimens to the genetic makeup of an individual. Facilitating this are novel biosensing approaches for in vitro diagnostics, developed at the interface of engineering, physics, chemistry and biology. New discoveries promise to sustain the high rate of growth of this important field of research and development. This chapter examines recent advances in techniques for biosensing and in vitro biomedical diagnostics, building on progress in materials science, nanotechnology, semiconductor devices, and biotechnology. The importance of this topic is motivated through the presentation of case studies of biosensing applications within various medical specialties.


Sign in / Sign up

Export Citation Format

Share Document